US Stock Insider Trading | Lyell Immunopharma Discloses 3 Insider Transactions on February 12

2026-03-07 01:28:03

Abstract generation in progress

On February 12, 2026, Lyell Immunopharma (LYEL) disclosed three insider trading transactions. Director Seely Lynn sold 7,455 shares on February 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
2026-02-12	Executive	Hill Stephen J.	2026-02-11	Sell	1,236	23.39	$28,900
2026-02-12	Director	Seely Lynn	2026-02-11	Sell	7,455	23.39	$174,400
2026-02-12	Executive	Lee Gary K.	2026-02-11	Sell	1,671	23.39	$39,100
2026-02-11	Executive	Lee Gary K.	2026-02-10	Sell	147	23.12	$3,398.64
2026-02-11	Executive	Hill Stephen J.	2026-02-10	Sell	109	23.12	$2,520.08
2026-02-11	Director	Seely Lynn	2026-02-10	Sell	438	23.12	$10,100
2026-02-11	Executive	Bulis Veronica Sanchez	2026-02-10	Sell	254	23.12	$5,872.48
2026-01-06	Executive	Bulis Veronica Sanchez	2025-12-30	Sell	936	32.32	$30,300
2025-12-24	Executive	Bulis Veronica Sanchez	2025-12-24	Sell	1,136	38.67	$43,900
2025-11-10	Executive	Bulis Veronica Sanchez	2025-11-10	Sell	239	16.10	$3,847.90

[Company Information]

Lyell Immunopharma, Inc. was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company expected to enter pivotal trials in 2025, advancing proprietary next-generation autologous CAR T-cell candidate pipelines for hematologic malignancies and solid tumors. The company is pioneering approaches to generate T cells that drive durable clinical responses. Patient’s live cells are the starting point for the company’s research-based CAR T-cell therapies, enhanced through innovative CAR structures, technologies, and manufacturing protocols.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.